share_log

多瑞医药:为进一步优化股权投资结构 拟收购控股子公司嘉诺康剩余20%股权

Dori Pharmaceutical: in order to further optimize the equity investment structure, it is proposed to acquire the remaining 20% stake in the holding subsidiary Jiaruokang.

發佈易 ·  Jan 21, 2022 01:20

Easy January 21-in order to further optimize the company's equity investment structure and improve the operational efficiency of the R & D platform, the company plans to use its own funds to acquire a 20 per cent stake in Wuhan Jiaruokang Pharmaceutical Technology Co., Ltd., a controlling subsidiary of Wuhan Pharmaceutical Technology Co., Ltd., according to the announcement of Douri Pharmaceutical (301075). The two sides of the transaction recently signed the "Equity transfer Agreement". Upon completion of the transaction, Jianokang will become a wholly owned subsidiary of the company.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment